Navigation Links
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
Date:8/8/2008

ory - 576

Other assets 51 (124)

Accounts payable 184 (6,507)

Accrued project costs 532 (702)

Payroll liabilities 547 (59)

Restricted stock unit liability 12 -

Deferred income 580 -

Asset retirement obligation - 295

Interest payable (5) -

Net cash used in operating activities (5,993) (18,697)

Investing activities

Decreases of short-term investments 4,857 12,044

Purchases of investments - (500)

Net cash provided by investing activities 4,857 11,544

Financing activities

Proceeds from issuance of common stock

Public Offering - 18,230

Issuance costs - (1,266)

Other 67 83

Total proceeds from issuance of common stock 67 17,047

Costs incurred in conjunction with issuance

of debt - -

Repayment of convertible notes (1,106) -

Other - 297

Net cash (used in) provided by financing

activities (1,039) 17,344

(Decrease) Increase in cash and cash

equivalents (2,175) 10,191

Cash and cash equiva
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Richmond, VA (PRWEB) November 21, 2014 ... businessman who understood the need to surround himself with ... visionary, CEO and entrepreneur, his friends often marveled at ... how he lived his life and -- even with ... cure for the Alzheimer’s disease that would ultimately take ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... 2014   , ... Officer zu KLOX    ... Financial Officer bestellt    KLOX ist ... jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... Offering a complete line of laboratory ... promotion . The Sartorius Entris Balance is the perfect ... and easy-to-maintain balance entry level balance. , The Entris ... to help customer’s bridge the gap between a basic ... very durable. Sartorius is the second biggest balance manufacturer ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2
... 20 percent of the world,s industrial production is based ... of chemical reactions by factors of billions. Oil, pharmaceuticals, ... Many are hoping to make current ... less pollution. Highly active and selective nanocatalysts, for example, ...
... (Nasdaq: MYL ) announced today that it will ... 3, 2011, at 8:30 a.m. ET, to review the company,s ... 31, 2011. Mylan will release its financial results on May ... to access the call is 800.479.9001 or 719.325.2146 for international ...
... April 20, 2011 In its first full year as a ... annual revenue by 55 percent over 2009 and grew Q4 revenue ... released today. Annual sales reached $5.4 million, up by ... million, up by $800,000 from the same quarter of 2009. ...
Cached Biology Technology:UCLA researchers now 1 step closer to controlled engineering of nanocatalysts 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 3
(Date:11/12/2014)... GARDENS, Fla. , Nov. 12, 2014 ... announced today that its U.are.U ® fingerprint readers ... bakery chain in Central Mexico . ... June 2014 to eliminate payroll issues caused by employees ... to installing the U.are.U fingerprint readers, Montparnasse relied on ...
(Date:11/7/2014)... 2014 Leading Biometric companies aim to ... revolutionizing online transactions.  Companies in focus today are: NXT-ID, Inc. ... BABA ), Google Inc. (NASDAQ: GOOG ), ... EBAY ) and MasterCard Inc. (NYSE: MA) ... a biometric authentication company focused on the growing mobile commerce ...
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... A new analysis has provided a comprehensive comparison of ... breast cancer are at high risk of recurrence beyond ... endocrine treatment. The promising new findings will likely ... whose cancer recurs more than five years after diagnosis, ...
... led by prominent breast cancer experts from Europe and ... prospects for targeted therapies, and brings opportunities of truly ... said at the 5th IMPAKT Breast Cancer Conference in ... ,translational, breast cancer research that is beginning to have ...
... healthy people have been bombarded by stories in the media ... vitamin D levels, and urging high doses of supplements to ... to diabetes. But new research from Johns Hopkins finds ... the top of the range suggested by the Institute of ...
Cached Biology News:Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 2Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer 3Study opens new prospects for developing new targeted therapies for breast cancer 2Study opens new prospects for developing new targeted therapies for breast cancer 3Vitamin D: More may not be better 2
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
...
Biology Products: